Inovio DNA Medicines Platform July 2020 Investor Presentation

Loading viewer...

investor_presentation

Format: PDF investor_presentation

Inovio presents its DNA medicine platform with clinical data from over 2,000 patients across multiple programs. The company showcases its first DNA medicine in Phase 3 trials (VGX-3100 for cervical dysplasia), advances in immunotherapy combinations, and proprietary plasmid delivery technology protected by extensive patents.

Browse all investor_presentations →

Related tags

Your message matters.

Let us design a presentation that delivers.

Lets get started

More from Inovio Pharmaceuticals

View all →

Inovio_230510-dna-medicines-and-hpv-may-2023

presentation

Similar investor_presentations from other companies

Browse all →

Credit Suisse Investor Presentation — September 2020

investor_presentation

48 Pages

Credit Suisse

Porsche SE London Roadshow 2024 Investor Presentation

investor_presentation